Lalitha Pereirasamy Malaysia

Senior Consultant Physician & Pulmonologist, Head of Department, Department of Respiratory Medicine, Penang General Hospital. Vice President, Malaysian Thoracic Society Scientific Chairman, APSR2026
Job Title
Consultant Physician and Pulmonologist
Faculty / Department / Division
Respiratory Medicine
Institution / Organisation
Hospital Pulau Pinang

20 November 2026, Friday

Time Session
09:30
11:00
Lalitha Pereirasamy Chairperson Malaysia
Umadevi A. Muthukumaru Chairperson Malaysia
  • Ernest Mau Ern Poh Speaker Malaysia
  • Anne Chang Speaker Australia
    "Therapeutic Advances in Bronchiectasis: Prof Anne B Chang Queensland University of Technology; Department of Respiratory and Sleep Medicine, Queensland Children’s Hospital, Brisbane; and Menzies School of Health Research, Darwin, Australia Bronchiectasis is coming of age with the realisation of its burden of disease on patients and health systems, combined with increased research and pharmaceutical interest with fresh therapeutics. Early therapeutics focused on using antibiotics. While the first use of inhaled antibacterial solutions for bronchiectasis occurred in 1892[1], specific inhaled antibiotics usage was initially extrapolated from CF data in the 1990s until the first RCT that targeted adults with bronchiectasis.[2] Treatment of bronchiectasis has advanced markedly since the adoption of Cole’s paradigm,[3] which has now evolved into the contemporary vortex model. Using this framework, therapeutic advances include optimised airway clearance strategies, long-term macrolide therapy, inhaled and systemic antibiotics for selected patients, and improved treatment pathways for exacerbations and chronic infection, rehabilitation, muco-active agents (for a subset) as well as specific treatment for different phenotypes.[4] Both neutrophil dominant and eosinophil phenotypes have emerged as a leading therapeutic focus. These have culminated in the development of a therapeutic pipeline of dipeptidyl peptidase 1 (DPP 1) inhibitors including brensocatib, verducatib and HSK31858. Together, these interventions have reduced exacerbation frequency and improved quality of life in appropriately selected patients, and DPP 1 has a disease-modifying effect. In parallel, greater attention is being given to nutrition, vaccination, comorbidities, and adherence to self-management plans, all of which contribute to treatment effectiveness. With respect to antibiotics, several pharmaceutical companies undertook large multicenter RCTs (e.g. AIR-BX, RESPIRE, ORBIT). Despite demonstrating reductions in airway bacterial load, these trials yielded mixed results for their primary clinical endpoints (mostly exacerbations).[5] While possible explanation for the variance include the heterogeneity in microbiome baseline status and geography[5], the latest systematic review (20 RCTs) generally favoured inhaled antibiotics (vs placebo) with reduced exacerbation frequency (RR=0.78, 95%CI 0.68, 0.91) and improved and QoL-Bronchiectasis respiratory symptom score (mean difference=2.51, 95%CI 0.44-4.31).[6] Bronchiectasis management has thus evolved from symptom control toward a more targeted approach. Emerging strategies are increasingly focused on precision medicine, including better risk stratification, biomarker development, and use of imaging and microbiologic data to guide therapy. Overall, therapeutic progress in bronchiectasis reflects a shift toward earlier intervention, prevention of exacerbations, and more personalized care. Despite these advances, important gaps remain in pediatric bronchiectasis, where high-quality evidence is still limited and most treatment decisions are extrapolated from adult data. References 1 Osler W. The principles and practice of medicine: designed for the use of practitioners and students of medicine. New York: D. Appleton and Company, 1892. 2 Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000; 162: 481-485. 3 Cole PJ. Inflammation: a two edged sword. The model of bronchiectasis. Eur J Respir Dis Suppl 1986; 147: 6-15. 4 Tramontano A, Caporaso M, Macciocchi G, et al. New Perspectives in the Treatment of Bronchiectasis. Arch Bronconeumol 2026; Jan 9:S0300-2896(26)00004-9. 5 Mac Aogain M. Beyond ORBIT: Mapping the Constellation of Pseudomonas Endotypes in Bronchiectasis Clinical Trials. Am J Respir Crit Care Med 2025; 211: 1321-1323. 6 Cordeiro R, Choi H, Haworth CS, et al. The Efficacy and Safety of Inhaled Antibiotics for the Treatment of Bronchiectasis in Adults: Updated Systematic Review and Meta-Analysis. Chest 2024; 166: 61-80. "
  • Herbert Wang Chun Kwok Speaker Hong Kong
    Co-morbidities are highly prevalent in non-cystic fibrosis bronchiectasis and serve as major drivers of disease severity, healthcare utilization, and mortality. While traditional clinical assessments focus primarily on pulmonary architecture, emerging evidence demonstrates that multimorbidity profoundly impacts patient prognosis, necessitating a shift toward comprehensive, multi-organ evaluation. This talk synthesizes current global registry data and international cohorts to examine the prevalence, pathophysiological mechanisms, and prognostic implications of respiratory, systemic, and psychological co-morbidities. Concomitant airway diseases such as COPD and asthma independently predict increased exacerbation frequency, accelerated FEV1 decline, and reduced survival, while chronic rhinosinusitis correlates with altered airway microbiology and type 2 inflammation. Systemic and metabolic complications—including diabetes mellitus, Vitamin D deficiency, and gastroesophageal reflux managed with high-dose proton pump inhibitors—are heavily associated with worse radiological severity, increased hospitalizations, and elevated all-cause mortality. Furthermore, bronchiectasis significantly escalates the risk of cardiovascular events and progressive renal decline, where renal impairment independently triples mortality risk. Dedicated risk stratification tools, such as the Bronchiectasis Aetiology Comorbidity Index (BACI), outperform generic comorbidity indices in predicting long-term survival. Recognizing, screening, and actively managing these extra-pulmonary and overlapping conditions is essential for delivering personalized care and improving long-term patient outcomes.
  • Q&A
Ballroom 3, Lower Ground Floor
14:00
15:00
Ernest Mau Ern Poh Chairperson Malaysia
Lalitha Pereirasamy Chairperson Malaysia
  • Michelle Gong Speaker United States
    Respiratory medicine's evidence base is skewed by Asia's near-absence from clinical trials, and that this is not merely an equity problem but a scientific one — Asia holds close to 60% of the world's population and therefore the largest absolute number of pneumonia deaths, yet the diversity within the continent is treated as a single category. The diversity extends to management and inflammatory profiles in ARDS. This has implications with personalized care and trials. Precision therapy already shows access disparities in Asia mirroring those documented for molecular testing in lung cancer elsewhere. Chronic disease phenotypes diverge as well — COPD risk centers more on biomass fuel and prior TB exposure than smoking; lung cancer shows higher rates of non-smoking adenocarcinoma and EGFR mutation; bronchiectasis trends toward post-TB incidence and a dry phenotype with lower bacterial burden; asthma sub-phenotypes vary country to country. But this diversity in Asia are also opportunities for research. This can be done by leveraging existing data sources and collecting new registry data (retrospective or prospective) to establish disease burden. One can start locally and then link data across sites. Collaborate for team science, and participate in pragmatic comparative-effectiveness and implementation trials that embed into routine care without placebo or drug preparation are also opportunities. Given limited resources, researchers should choose questions no one has answered locally and collect only the key data that can be done routinely during clinical practice. Professional meetings are an important route to multi-country teams and research. One key element is the need to invest in training physicians in research methods so that they can lead research in their own country. ATS MECOR (Methods in Epidemiologic, Clinical and Operations Research) is one model for building that capacity.
  • Shigeo Muro Speaker Japan
    Respiratory medicine increasingly relies on evidence generated across different populations. Yet clinical findings from one region may not fully describe patients in another. Asia is highly diverse, and differences may exist both between Asian and Western patient groups and among populations within Asia. As an example of diversity within Asia, the frequency of EGFR mutations in lung adenocarcinoma varies across Asian populations. Turning to COPD, selected observational studies from Asia, Europe and the United States suggest differences in body mass index, chronic bronchitis and exacerbation history across the groups studied. These findings should not be taken as uniform characteristics of all Asian patients. Breathlessness, reduced daily activity and long-term outcomes also deserve attention, even when exacerbations are less frequent. Another major challenge is underdiagnosis. Studies from Japan, Korea and China have identified gaps in COPD diagnosis or previous spirometry use. Efforts to address these gaps must take local healthcare systems and resources into account. Japan's Health Japan 21 programme includes a national target to reduce COPD mortality. To support this goal, the Japanese Respiratory Society is pursuing COMORE-By2032, an ongoing initiative that links public awareness and earlier medical visits with spirometry, smoking cessation and continued care. Global evidence is essential, but improving COPD care also requires locally appropriate action and collaboration across the Asia-Pacific region.
  • Marc Miravitlles Speaker Spain
  • Q&A
Ballroom 4, Lower Ground Floor
15:00
16:00
Sponsored by AstraZeneca
Lalitha Pereirasamy Chairperson Malaysia
Ballroom 3, Lower Ground Floor

21 November 2026, Saturday

Time Session
08:30
09:00
Advancing COPD Care: From Phenotypes to Targeting Treatable Traits Through Precision Medicine
Marc Miravitlles Speaker Spain
Lalitha Pereirasamy Chairperson Malaysia
"Advancing COPD Care: From Phenotypes to Targeting Treatable Traits Through Precision Medicine Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition characterised by substantial variability in clinical presentation, underlying biological mechanisms, disease trajectory and response to treatment. This heterogeneity has challenged the traditional approach of classifying patients according to fixed clinical phenotypes and applying largely uniform treatment strategies. Increasing evidence supports a shift towards precision medicine, in which treatment decisions are guided by the identification of individual, measurable and clinically relevant treatable traits. The concept of treatable traits represents an evolution from phenotype-based classification towards a multidimensional assessment of the patient. Rather than assigning patients to mutually exclusive categories, this approach recognises that several clinically relevant traits may coexist within the same individual and may change over time. These traits can encompass pulmonary characteristics, such as airflow limitation, hyperinflation, emphysema, chronic bronchitis, bronchiectasis and chronic bronchial infection, as well as systemic and extrapulmonary features including cardiovascular disease, frailty, osteoporosis, skeletal muscle dysfunction, anxiety and depression, and physical inactivity. Importantly, treatable traits should not simply describe disease characteristics; they should identify clinically relevant abnormalities for which an effective intervention is available. This distinction is particularly relevant as therapeutic options for COPD continue to expand. Blood eosinophil counts, for example, can help identify patients who are more likely to benefit from inhaled corticosteroids and, more recently, from targeted biologic therapies. Similarly, frequent exacerbations, chronic bronchial infection, mucus hypersecretion, pulmonary hyperinflation and physical inactivity may each require different therapeutic strategies, ranging from pharmacological treatment to pulmonary rehabilitation, airway clearance, antimicrobial approaches or interventions aimed at reducing hyperinflation. The emergence of biologic therapies targeting specific inflammatory pathways represents an important step towards precision treatment in COPD. However, precision medicine should not be equated with precision pharmacotherapy. Its broader objective is to integrate clinical characteristics, biomarkers, imaging, physiological measurements, comorbidities, environmental exposures and patient-reported outcomes to construct an individualised disease profile and select interventions according to the dominant treatable traits. Future COPD management will therefore require dynamic rather than static patient characterisation. Treatable traits may evolve with disease progression, exacerbations, treatment and ageing, making repeated assessment essential. Digital health, artificial intelligence, multi-omics and increasingly accessible biomarkers may further improve phenotyping and prediction of treatment response. The transition from phenotypes to treatable traits offers an opportunity to move beyond a one-size-fits-all model of COPD care. The challenge now is to determine which traits are clinically meaningful, how they should be identified and prioritised, and whether treating them translates into better outcomes. Precision medicine in COPD should ultimately be judged not by the sophistication of patient classification, but by its capacity to deliver more effective, personalised and clinically meaningful care."
Ballroom 3, Lower Ground Floor
09:00
09:30
Translational Research on the Development of Antifibrotic Drugs for Pulmonary Fibrosis and Lung Cancer
Yasuhiko Nishioka Speaker Japan
Lalitha Pereirasamy Chairperson Malaysia
Ballroom 3, Lower Ground Floor

22 November 2026, Sunday

Time Session
12:00
13:00
Irfhan Ali Hyder Ali Chairperson Malaysia
Justin Yu Kuan Tan Chairperson Malaysia
  • Pang Yong Kek Speaker Malaysia
    S34 - Haematological Disorder and Lungs By Yong Kek, Pang Following allogeneic haematopoietic stem cell transplantation (alloHSCT), pulmonary graft-versus-host disease (pGVHD) represents a serious complication driven by alloreactive donor immune cells, conditioning therapies, and infections. Acute manifestations present within 100 days primarily as pneumonia or bronchitis, whereas chronic pGVHD manifests beyond 100 days as bronchiolitis obliterans syndrome (BOS), interstitial lung disease (ILD), or rare vascular complications. Chronic pGVHD has an estimated cumulative incidence of ~20% within two years post-transplant, with BOS accounting for 56.4% and ILD for 30.8% of non-infectious complications. Because clinical onset is often indolent—and many patients are identified only after 40% to 50% of lung function is lost—early detection through structured surveillance is essential to prevent progressive, irreversible injury. Surveillance protocols recommend baseline and routine spirometry at 3 months, 6 months, and annually for 2 years post-transplant, with accelerated testing after acute flares or immunosuppression tapering. Patients with chronic pGVHD warrant spirometry at least every 6 months and annual full pulmonary function testing. Complementary assessments, including high-resolution CT (HRCT), 6-minute walk tests, and multidisciplinary reviews, are critical to exclude alternative pathologies and guide therapy.
  • Yet Hong Khor Speaker Australia
    Connective tissue diseases (CTDs) are increasingly prevalent, with lung involvement being common, which contributes to substantial morbidity and mortality. Lung involvement in CTD encompasses a broad spectrum of manifestations affecting the airways, lung parenchyma, pleura, pulmonary vasculature and respiratory muscles. Interstitial lung disease (ILD) represents one of the most frequent and clinically significant manifestations. Importantly, lung involvement may precede extra-pulmonary manifestations of CTD, creating diagnostic challenges for respiratory physicians. This presentation will provide a practical overview of the relationship between CTD and lung disease, with a particular focus on CTD-associated ILD. Management principles will also be explored, including multidisciplinary care models and the importance of tailoring treatment according to disease stage, underlying inflammatory and fibrotic mechanisms, and treatment goals. Bronchiolar disease and treatment-related pulmonary complications in CTD will be highlighted. The discussion aims to equip clinicians with practical strategies for the diagnosis and management of CTD-related lung disease in clinical practice.
  • Lalitha Pereirasamy Speaker Malaysia
    COPD and cardiovascular disease (CVD) frequently coexist and amplify each other, yet are usually managed separately. They share risk factors such as smoking, ageing and air pollution. Around half of COPD deaths are cardiovascular, and 7–30% of patients with acute myocardial infarction (AMI) have COPD. This presentation brings together recent reviews, a 24-study systematic review, and key cohort and trial data on the mechanisms linking COPD and CVD. It focuses on systemic inflammation and shared biomarkers. COPD confers a risk of major adverse cardiovascular events comparable to diabetes (adjusted HR 1.50 vs 1.41). It nearly triples heart failure risk, with the greatest excess in younger patients. The continuum begins early: low or declining FEV₁, even within normal limits, predicts heart failure, atrial fibrillation and stroke. Five bridges link the organs: systemic inflammation, hypoxaemia, pulmonary vascular remodelling, hyperinflation and autonomic dysfunction. Lung injury activates NF-κB and the NLRP3 inflammasome. IL-1β, IL-6, IL-8 and TNF-α then spill into the circulation, driving endothelial dysfunction, platelet activation and plaque instability. Exacerbations act as a “second hit”: cardiovascular event risk rises 22-fold during severe exacerbations, and AMI risk is eightfold in the first three days. IL-1 blockade is a promising shared target but remains untested in patients with both conditions. Conclusion :NT-proBNP, troponin, coronary artery calcium on chest CT and spirometry are ready for routine use. CRP, fibrinogen, neutrophil-to-lymphocyte ratio and heart rate variability are useful adjuncts. Every exacerbation should be treated as a cardiovascular risk window, with integrated pulmonology–cardiology care.
  • Q&A
Ballroom 2, Lower Ground Floor